Oksana A Shlobin
Overview
Explore the profile of Oksana A Shlobin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
1845
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Shlobin O, Shen E, Wort S, Piccari L, Scandurra J, Hassoun P, et al.
Pulm Circ
. 2024 Jan;
14(1):e12310.
PMID: 38205098
Pulmonary hypertension (PH) due to interstitial lung disease (ILD), a commonly encountered complication of fibrotic ILDs, is associated with significant morbidity and mortality. Until recently, the studies of pulmonary vasodilator...
12.
Nathan S, Tehrani B, Zhao Q, Arias R, Kim D, Pellegrini A, et al.
Pulm Circ
. 2024 Jan;
14(1):e12311.
PMID: 38174158
Pulmonary vascular dysfunction in the absence of pulmonary hypertension (PH) has been observed in patients with idiopathic pulmonary fibrosis (IPF). We describe the prevalence and etiology of elevated pulmonary vascular...
13.
Khangoora V, Bernstein E, King C, Shlobin O
Pulm Circ
. 2023 Dec;
13(4):e12276.
PMID: 38088955
Connective tissue diseases (CTDs) can be associated with various forms of pulmonary hypertension, including pulmonary arterial hypertension (PAH), pulmonary veno-occlusive disease, pulmonary venous hypertension, interstitial lung disease-associated pulmonary hypertension, chronic...
14.
Gayen S, Baughman R, Nathan S, Wells A, Kouranos V, Alhamad E, et al.
Pulm Circ
. 2023 Oct;
13(4):e12297.
PMID: 37840561
Pulmonary hypertension (PH) is a risk factor for mortality in patients with sarcoidosis. Severe PH in chronic lung disease has previously been defined as mean pulmonary arterial pressure (mPAP) ≥ ...
15.
King C, White E, Aryal S, Shlobin O, Singhal A, Brown A, et al.
Heliyon
. 2023 Aug;
9(8):e18618.
PMID: 37600402
Rationale And Objectives: Lung transplantation is a potentially life-saving treatment option for patients with idiopathic pulmonary fibrosis (IPF); however, not all eligible candidates get referred and listed for transplantation. Amongst...
16.
Chandel A, King C, Ignacio R, Pastre J, Shlobin O, Khangoora V, et al.
ERJ Open Res
. 2023 May;
9(3).
PMID: 37228268
Background: The Distance-Oxygen-Gender-Age-Physiology (DO-GAP) index has been shown to improve prognostication in idiopathic pulmonary fibrosis (IPF) compared to the Gender-Age-Physiology (GAP) score. We sought to externally validate the DO-GAP index...
17.
Forfia P, Benza R, DAlto M, De Marco T, Elwing J, Frantz R, et al.
Pulm Circ
. 2023 May;
13(2):e12240.
PMID: 37222992
Right heart (RH) structure and function are major determinants of symptoms and prognosis in pulmonary arterial hypertension (PAH). RH imaging provides detailed information, but evidence and guidelines on the use...
18.
Piccari L, Allwood B, Antoniou K, Chung J, Hassoun P, Nikkho S, et al.
Pulm Circ
. 2023 Apr;
13(2):e12213.
PMID: 37025209
Pulmonary hypertension (PH) is a frequent complication of interstitial lung disease (ILD). Although PH has mostly been described in idiopathic pulmonary fibrosis, it can manifest in association with many other...
19.
McCormick A, Krishnan A, Badesch D, Benza R, Bull T, De Marco T, et al.
Heart
. 2023 Feb;
109(14):1098-1105.
PMID: 36787969
Objective: Pulmonary artery compliance (PAC), estimated as stroke volume (SV) divided by pulmonary artery pulse pressure (PP), may be a predictor of survival in pulmonary arterial hypertension (PAH). Resistance-compliance (RC)...
20.
Rahaghi F, Hsu V, Kaner R, Mayes M, Rosas I, Saggar R, et al.
Respir Res
. 2023 Jan;
24(1):6.
PMID: 36624431
Background: Systemic sclerosis (SSc) is a rare, complex, connective tissue disorder. Interstitial lung disease (ILD) is common in SSc, occurring in 35-52% of patients and accounting for 20-40% of mortality....